Balance Sheet

Accounts Payables Accumulated Expenses Assets Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Finished Goods Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Non-Current Assets Non-Current Debt Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Shares Prepaid Assets Property, Plant & Equipment (Net)Raw Materials Receivables Retained Earnings Shareholder's Equity Shares Outstanding Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Aytu Biopharma (AYTU) Non-Current Deferred Tax Liability (2021 - 2023)

Aytu Biopharma (AYTU) has disclosed Non-Current Deferred Tax Liability for 2 consecutive years, with $100000.0 as the latest value for Q4 2021.

On a quarterly basis, Non-Current Deferred Tax Liability changed N/A to $100000.0 in Q4 2021 year-over-year; TTM through Dec 2021 was $100000.0, a N/A change, with the full-year FY2021 number at $200000.0, changed N/A from a year prior.
Non-Current Deferred Tax Liability was $100000.0 for Q4 2021 at Aytu Biopharma, roughly flat from $100000.0 in the prior quarter.
In the past five years, Non-Current Deferred Tax Liability ranged from a high of $200000.0 in Q2 2021 to a low of $100000.0 in Q3 2021.